William Blair Investment Management LLC Purchases 269,896 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

William Blair Investment Management LLC raised its holdings in Blueprint Medicines Co. (NASDAQ:BPMC) by 16.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,944,695 shares of the biotechnology company’s stock after buying an additional 269,896 shares during the period. William Blair Investment Management LLC owned 3.06% of Blueprint Medicines worth $169,616,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in BPMC. S&CO Inc. boosted its holdings in Blueprint Medicines by 49.3% in the 3rd quarter. S&CO Inc. now owns 10,000 shares of the biotechnology company’s stock valued at $925,000 after purchasing an additional 3,300 shares during the period. Swiss National Bank grew its holdings in Blueprint Medicines by 1.6% during the 3rd quarter. Swiss National Bank now owns 116,200 shares of the biotechnology company’s stock worth $10,748,000 after acquiring an additional 1,800 shares during the last quarter. Segall Bryant & Hamill LLC grew its holdings in Blueprint Medicines by 11.6% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 141,622 shares of the biotechnology company’s stock worth $13,100,000 after acquiring an additional 14,668 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Blueprint Medicines in the 3rd quarter valued at $475,000. Finally, Advisors Asset Management Inc. boosted its stake in Blueprint Medicines by 17.6% during the third quarter. Advisors Asset Management Inc. now owns 5,054 shares of the biotechnology company’s stock worth $467,000 after acquiring an additional 756 shares in the last quarter.

Blueprint Medicines Stock Performance

Shares of NASDAQ:BPMC opened at $89.58 on Monday. The firm has a market capitalization of $5.72 billion, a PE ratio of -82.94 and a beta of 0.58. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The business has a 50-day moving average of $99.54 and a two-hundred day moving average of $94.04. Blueprint Medicines Co. has a 12 month low of $80.68 and a 12 month high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. As a group, research analysts forecast that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. StockNews.com downgraded shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Monday, March 3rd. Guggenheim reaffirmed a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. JPMorgan Chase & Co. increased their price target on shares of Blueprint Medicines from $126.00 to $129.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Stephens reissued an “overweight” rating and issued a $140.00 price objective on shares of Blueprint Medicines in a report on Thursday, January 2nd. Finally, Piper Sandler lifted their price objective on shares of Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $125.21.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, insider Ariel Hurley sold 2,250 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $100.00, for a total transaction of $225,000.00. Following the completion of the sale, the insider now owns 14,967 shares of the company’s stock, valued at $1,496,700. This represents a 13.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey W. Albers sold 15,000 shares of the firm’s stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $89.77, for a total value of $1,346,550.00. Following the completion of the transaction, the director now directly owns 157,557 shares of the company’s stock, valued at approximately $14,143,891.89. This trade represents a 8.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 46,608 shares of company stock valued at $4,668,161. 4.21% of the stock is owned by insiders.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.